Precigen price target raised to $10 from $7 at Cantor Fitzgerald

Cantor Fitzgerald analyst Jennifer Kim raised the firm’s price target on Precigen to $10 from $7 and keeps an Overweight rating on the shares following the company’s showcase of complete clinical trial safety and efficacy data from the Phase 1 dose-escalation and expansion cohorts for PRGN-2012 for recurrent respiratory papillomatosis. PRGN-2012’s data checked every box, and had the best efficacy and safety data the firm has seen for a therapeutic vaccine in RRP, which could support upwards of a greater than$1B market opportunity in the U.S., the analyst tells investors in a research note.